chloroform dimethyl sulfoxide | 38862-41-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 英文名称: chloroform dimethyl sulfoxide
• 英文别名: Chloroform - Dimethylsulfoxid Komplex；Dimethylsulfoxide chloroform；chloroform;methylsulfinylmethane
• CAS: 38862-41-8；120395-60-0；148555-86-6
• 化学式: CHCl₃*C₂H₆OS
• 分子量: 197.513
• InChiKey: RZWZDIVNLQZHGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.98
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  氯仿 、 二甲基亚砜 生成 chloroform dimethyl sulfoxide
  参考文献：
  名称：

  二甲基亚砜与三氯甲烷和二氯甲烷的分子络合物

  摘要：

  二甲基亚砜与三氯甲烷（氯仿），（CH 3）2 SO·2CHCl 3（I）和二氯甲烷（CH 3）2 SO·CH 2 Cl 2（II）的分子络合物晶体已在原地。在这两种化合物中，各组分通过（Cl）C-H ... O相互作用连接在一起。（I）中的二甲基亚砜分子通过CHH ... O相互作用结合成链。在（II）中，成对的组分形成中心对称的环，通过C-H ... O接触和二甲亚砜分子之间的偶极-偶极相互作用将其连接成三维网络。

  DOI：

  10.1107/s0108270111056265
• 作为试剂：
  描述：

  (2R,3R,4S,5R)-2-[2-((R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-5-(2-ethyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol trifluoroacetate 、 3-异氰酸吡啶 在 乙腈 、 水 作用下， 以 chloroform dimethyl sulfoxide 为溶剂， 反应 3.0h， 以water (0.1% TFA) (gradient of 0-100% acetonitrile) to afford the titled compound的产率得到1-((R)-1-{6-(2,2-diphenyl-ethylamino)-9-[(2R,3R,4S,5R)-5-(2-ethyl-2H-tetrazol-5-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-9H-purin-2-yl}-pyrrolidin-3-yl)-3-pyridin-3-yl-urea trifluoroacetate
  参考文献：
  名称：

  Organic Compounds

  摘要：

  化合物(I)或其立体异构体或药学上可接受的盐，其中W、R1、R2、R3和R4的含义如规范中所示，可用于治疗通过激活腺苷A2A受体介导的炎症或阻塞性呼吸道疾病。本文还描述了含有该化合物的药物组合物和制备该化合物的方法。

  公开号：

  US20080242683A1

文献信息

• Compound and its use in electrochromic devices
  申请人：UNIVERSITY COLLEGE DUBLIN

  公开号：EP1500969A1

  公开（公告）日：2005-01-26

  This invention concerns a compound of any of the formulae V, VI or VII wherein X in formula V is S or O and R8-R10 are each independently selected from the following:         HO(CH2)n―         HOOC(CH2)n―         (HO)2B(CH2)n―         (R11O)3Si(CH2)n― wherein R11 is C1-10 alkyl and n = 1-10. These compounds are suitable for use in electrochromic devices.

  这项发明涉及任一式V、VI或VII的化合物，其中式V中的X为S或O，而R8-R10分别独立地选自以下物质：HO(CH2)n―、HOOC(CH2)n―、(HO)2B(CH2)n―、(R11O)3Si(CH2)n―，其中R11为C1-10烷基，n = 1-10。这些化合物适用于用于电致变色器件。
• [EN] ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS<br/>[FR] DERIVES D'ALPHA-CETOAMIDE UTILISES EN TANT QU'INHIBITEURS DE LA CATHEPSINE K
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003013518A1

  公开（公告）日：2003-02-20

  Biaryl ketoamide derivatives (I), which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such biaryl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.

  本文描述了有用于作为蛋白酶K抑制剂的双芳基酮酰胺衍生物(I)。所述的发明还包括制备这种双芳基酮酰胺衍生物的方法，以及在治疗与增强骨转换相关的疾病，包括骨质疏松症，最终可能导致骨折的方法。
• Alpha-ketoamide derivatives as cathepsin k inhibitors
  申请人：Barrett David Gene

  公开号：US20050107616A1

  公开（公告）日：2005-05-19

  Biaryl ketoamide derivatives, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such biaryl ketoamide derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis, associated with enhanced bone turnover which can ultimately lead to fracture.

  本文介绍了用作猫hepsin K抑制剂的联苯基酮酰胺衍生物。所述发明还包括制备这种联苯基酮酰胺衍生物的方法，以及将其用于治疗与增强骨转换有关的疾病，包括骨质疏松症，该疾病最终可能导致骨折的方法。
• Methods and compositions for the efficient delivery of therapeutic agents to cells and animals
  申请人：Rana M. Tariq

  公开号：US20070260055A1

  公开（公告）日：2007-11-08

  The present invention provides methods of carrying out the safe and reliable preparation of lipids comprising quaternary amines. Such lipids are especially suited for introducing therapeutic agents into cells or organisms. In particular, the lipids of the invention are suitable for the efficient transfer of gene therapy agents into mammalian cells or organisms in a cell type specific or tissue specific manner.

  本发明提供了一种安全可靠的制备含季铵盐脂质的方法。这种脂质特别适合将治疗剂介入细胞或生物体中。特别是，本发明的脂质适用于以细胞类型特异性或组织特异性的方式高效地将基因治疗剂转移到哺乳动物细胞或生物体中。
• C-PHENYL 1-THIOGLUCITOL COMPOUND
  申请人：Kakinuma Hiroyuki

  公开号：US20100004465A1

  公开（公告）日：2010-01-07

  C-phenyl 1-thioglucitol compounds of the following formula (I) or pharmaceutically acceptable salts thereof or hydrates thereof: [wherein X represents a hydrogen atom or a C 1-6 alkyl group, Y represents a C 1-6 alkylene group or —O—(CH 2 )n- (wherein n represents an integer of 1 to 5), and Z represents —CONHR A or —NHCONHR B (provided that when Z represents —NHCONHR B , n is not 1), wherein R A represents a C 1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH 2 , and R B represents a hydrogen atom or a C 1-6 alkyl group substituted with 1 to 3 substituents selected from the group consisting of a hydroxyl group and —CONH 2 ] are useful as prophylactic or therapeutic agents for diabetes, because of their suppressive effect on sugar (e.g., glucose) absorption through inhibition of SGLT1 activity, or alternatively, because of their suppressive effect on sugar (e.g., glucose) absorption and excretory effect on urinary sugars through inhibition of both SGLT1 and SGLT2 activities.

  以下公式（I）的C-苯基1-硫代葡萄糖醇化合物或其药学上可接受的盐或水合物是糖尿病的预防或治疗药物，因为它们通过抑制SGLT1活性对糖（例如葡萄糖）吸收具有抑制作用，或者通过抑制SGLT1和SGLT2活性对糖（例如葡萄糖）吸收和尿糖排泄具有抑制作用。其中X代表氢原子或C1-6烷基，Y代表C1-6烷基或-O-（CH2）n-（其中n表示1至5的整数）的烷基，Z代表—CONHRA或—NHCONHRB（但当Z代表—NHCONHRB时，n不为1），其中RA代表C1-6烷基，其被1至3个取自氢氧基和—CONH2的基团取代，而RB代表氢原子或C1-6烷基，其被1至3个取自氢氧基和—CONH2的基团取代。